COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
Share price
−$10.93 (−32.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
COLLEGIUM PHARMACEUTICAL, INC grew revenue 14.3% to $808.21M over the twelve months to Jun 30, 2026. Operating income rose 21.3% to $157.44M, moving the operating margin from 18.4% to 19.5%. Free cash flow was $328.28M, up 62.7% from a year earlier.
Revenue
$808.21M
+14.3% vs. a year earlier
Operating income
$157.44M
+21.3% vs. a year earlier
Free cash flow
$328.28M
+62.7% vs. a year earlier
EPS, diluted
$1.24
+19.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $746.92M
- P/E ratio
- 18.6
- Price to sales
- 0.92
- Price to book
- 2.39
- Dividend yield
- –
- Free cash flow yield
- 43.95%
Fundamentals
- Revenue
- $808.21M
- Net income
- $47.92M
- EPS, diluted
- $1.24
- Free cash flow
- $328.28M
- Book value per share
- $9.61
- Diluted shares
- 32M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$808.21M+14.3% YoY
Gross profit
$485.09M+21.0% YoY
Operating income
$157.44M+21.3% YoY
Net income
$47.92M+32.1% YoY
EPS, diluted
$1.24+19.2% YoY
Free cash flow
$328.28M+62.7% YoY
Reported periodTrailing twelve months